Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ

Jung Hoon Kim, Manhyung Jeong, Sang Sik Lee, Jaewhan Song

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Camptothecin is an anti-cancer drug extracted from Camptotheca acuminata, a tree native to mainland China. Phase III clinical trials for camptothecin have been completed, and it is now used as a chemotherapeutic reagent. We identified a novel function of camptothecin that affects adipocyte differentiation. Following treatment with camptothecin, endogenous or overexpressed PPARγ becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor. Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARγ. The ubiquitylation of PPARγ increased in the presence of camptothecin. Adipogenic differentiation of 3T3-L1 cells was prevented by campothecin and topotecan, but not by irinotecan, confirming our initial findings. Our results suggest a possible role for camptothecin analogs in the regulation of PPARγ.

Original languageEnglish
Pages (from-to)1122-1128
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number4
Publication statusPublished - 2015 Jul 13

Bibliographical note

Funding Information:
This study was supported by the National Cancer Center , Korea ( NCC-1420300 ), and by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which was funded by the Ministry of Health & Welfare of the Republic of Korea ( HI12C1280 ).

Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ'. Together they form a unique fingerprint.

Cite this